Mathias Haenel

Addition of cyclophosphamide on insufficient response to pomalidomide and dexamethasone: results of the phase II PERSPECTIVE Multiple Myeloma trial

D. Hose, H. Goldschmidt, A. Jauch, 2019, Blood Cancer Journal.

Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients wi

D. Hose, H. Goldschmidt, A. Jauch, 2016, BMC Cancer.

Increased LFS Following Hematopoietic Cell Transplantation As Compared to Conventional Consolidation Therapy in Patients >60 Years with AML in First Complete Remission and a Matched Donor: Results of a Randomized Phase III Study

S. Iacobelli, D. Hasenclever, M. Mohty, 2022, Blood.

Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma

D. Hose, H. Goldschmidt, A. Jauch, 2019, BMC Cancer.

Profound impact of sample processing delay on gene expression of multiple myeloma plasma cells

D. Hose, H. Goldschmidt, G. Morgan, 2015, BMC Medical Genomics.

Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS

H. Goldschmidt, A. Oriol, P. Moreau, 2023, Blood Cancer Journal.

Inotuzumab Ozogamicin Induction Followed By Standard Chemotherapy Yields High Remission Rates and Promising Survival in Older (>55 Years) Patients with De Novo B-Lymphoblastic Leukemia (GMALL-Initial1 Trial)

G. Lenz, S. Raffel, S. Scholl, 2022, Blood.

Radiation and Dose-densification of R-CHOP in Aggressive B-cell Lymphoma With Intermediate Prognosis: The UNFOLDER Study

A. Rosenwald, M. Ziepert, N. Schmitz, 2023, HemaSphere.

CNS disease in younger patients with aggressive B-cell lymphoma: an analysis of patients treated on the Mabthera International Trial and trials of the German High-Grade Non-Hodgkin Lymphoma Study Group.

N. Schmitz, M. Pfreundschuh, M. Loeffler, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Carfilzomib, lenalidomide and dexamethasone followed by a second ASCT is an effective strategy in first relapse multiple myeloma: a study on behalf of the Chronic malignancies working party of the EBMT.

J. Bourhis, I. Yakoub-Agha, D. Mclornan, 2023, Bone marrow transplantation.

Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results

S. Trudel, M. Tomasson, S. Iida, 2023, Nature Medicine.